FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of September 2026
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Director/PDMR Shareholding
15 September 2026
Transaction by Person Discharging Managerial
Responsibilities
AstraZeneca PLC (the Company) announced that, on 14 September 2026,
Dr Aradhana Sarin, Chief Financial Officer of the Company, acquired
73 of the Company's ordinary shares of $0.25 each (Ordinary Shares)
following the vesting of certain dividend equivalent awards accrued
in relation to her 2021 AstraZeneca Performance Share Plan (AZPSP)
award.
The underlying 2021 AZPSP award vested to Dr Sarin on 17 August
2026 and was announced on 18 August 2026. Due to administrative
processing timelines, the dividend equivalent awards relating to
the Company's first interim dividend for 2026 were not included in
that vesting. These dividend equivalent awards therefore vested
separately on 14 September 2026. All other dividend equivalent
units accrued during the performance and holding period were
included within the 17 August vest.
Following the withholding of shares to satisfy certain tax
obligations arising on vesting, Dr Sarin's beneficial interest in
Ordinary Shares changed as detailed in the table
below:
|
PDMR
|
Position
|
Ordinary Shares acquired
|
|
Aradhana Sarin
|
Executive Director and Chief Financial Officer
|
73
|
For tax purposes, the fair market value of an Ordinary Share at
vest of the award was £114.60, being the closing price on the
last trading day preceding the vesting of the 2021 AZPSP
award.
Further details are set out in the attached notification, made in
accordance with the requirements of the EU Market Abuse Regulation
(as it forms part of UK law pursuant to the European Union
(Withdrawal) Act 2018).
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
|
a)
|
Name
|
Aradhana Sarin
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Financial Officer
|
|
b)
|
Initial notification /Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
AstraZeneca PLC
|
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type of
instrument
Identification code
|
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
|
b)
|
Nature of the transaction
|
Acquisition of shares following the reinvestment of certain
dividends accrued during the deferral period of the 2021
AstraZeneca Performance Share Plan award.
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
0
|
73
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
|
e)
|
Date of the transaction
|
14 September 2026
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Disease, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on Social Media @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date: 15 September 2026
|
|
By: /s/
Matthew Bowden
|
|
|
Name:
Matthew Bowden
|
|
|
Title:
Company Secretary
|
